Nanobiotix, pioneer and leader in nanomedicine, has developed a revolutionary concept dedicated to the local treatment of cancer.
Nanobiotix is focused on the development of NanoXray, a pipeline of patented products, which are based on a physical mechanism of action: nanoparticles interact with X-rays and enhance the effect of radiotherapy within tumour cells.
Nanobiotix is listed on NYSE Euronext (NANO).
65 Gresham Street,
London, EC2V 7NQ
T: +44 (0)20 7457 2020
© 2017 Instinctif Partners – Registered in England & Wales No 1036926 / VAT No 245666930 | visit our global website instinctif.com